Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vivo CRISPR screening identifies POU3F3 as a novel regulator of ferroptosis resistance in hepatocellular carcinoma via retinoic acid signaling

10 Jul 2025

Abstract excerpt

BACKGROUND: Sorafenib, a ferroptosis agonist, is a first-line treatment for advanced hepatocellular carcinoma (HCC). However, its clinical efficacy is limited due to drug resistance, resulting in modest improvements in patient survival. Hence, the present study has been designed to identify critical molecular targets associated with sorafenib resistance and investigate the potential inhibitors in overcoming this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Lipids, and Metabolism
Share to Cancer Mechanisms and Therapy
Share to Ferroptosis and cancer prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40634958
DOI: 10.1186/s12964-025-02285-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vivo CRISPR screening identifies POU3F3 as a novel regulator of ferroptosis resistance in hepatocellular carcinoma via retinoic acid signalingPMID 40634958Read ↗

CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinomaSemantic proximity Read ↗

Transcription factor MEF2D regulates aberrant expression of ACSL3 and enhances sorafenib resistance by inhibiting ferroptosis in HCCSemantic proximity Read ↗

CRISPR/Cas9 screening reveals that ASB2 inhibits p53-dependent ferroptosis to mediates Lenvatinib resistance in hepatocellular carcinomaSemantic proximity Read ↗

Identification of ferroptosis and drug resistance related hub genes to predict the prognosis in Hepatocellular CarcinomaSemantic proximity Read ↗

EZH2 Suppresses Ferroptosis in Hepatocellular Carcinoma and Reduces Sorafenib Sensitivity Through Epigenetic Regulation of TFR2Semantic proximity Read ↗

The Expression of Ferroptosis-Related Genes in Hepatocellular Carcinoma and Their Relationships With PrognosisSemantic proximity Read ↗

Role of ferroptosis in hepatocellular carcinoma.Semantic proximity Read ↗

Hepatoblastoma: an investigation of diagnostic, prognostic, and therapeutic gene targets and biomarkers.Semantic proximity Read ↗

The BRD7-P53-SLC25A28 axis regulates ferroptosis in hepatic stellate cellsSemantic proximity Read ↗

URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers.Semantic proximity Read ↗

Artesunate Sensitizes human hepatocellular carcinoma to sorafenib via exacerbating AFAP1L2-SRC-FUNDC1 axis-dependent mitophagySemantic proximity Read ↗

Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCCSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.